ADCETRIS is a brand name for the medication brentuximab vedotin, which is used in the treatment of certain types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It is classified as an antibody-drug conjugate (ADC), which combines an antibody that specifically targets cancer cells with a cytotoxic agent designed to kill those cells. ADCETRIS works by targeting the CD30 protein on the surface of some cancer cells, delivering the cytotoxic agent directly to them, which helps minimize damage to normal cells. It is typically administered through intravenous infusion and is used in patients who have not responded to other treatments or whose cancer has relapsed. The use of ADCETRIS has been associated with significant improvements in outcomes for patients with these types of cancer, but it can also cause serious side effects, which necessitates careful monitoring by healthcare professionals.